These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
376 related articles for article (PubMed ID: 31555967)
1. Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma. Consoli F; Bersanelli M; Perego G; Grisanti S; Merelli B; Berruti A; Petrelli F Clin Transl Oncol; 2020 Jun; 22(6):900-907. PubMed ID: 31555967 [TBL] [Abstract][Full Text] [Related]
2. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941 [TBL] [Abstract][Full Text] [Related]
3. [Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma]. Sibaud V; Baric L; Cantagrel A; Di Palma M; Ederhy S; Paques M; Perlemuter G Bull Cancer; 2021 May; 108(5):528-543. PubMed ID: 33812673 [TBL] [Abstract][Full Text] [Related]
4. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. Daud A; Gill J; Kamra S; Chen L; Ahuja A J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762 [TBL] [Abstract][Full Text] [Related]
5. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898 [TBL] [Abstract][Full Text] [Related]
6. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. Devji T; Levine O; Neupane B; Beyene J; Xie F JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543 [TBL] [Abstract][Full Text] [Related]
7. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705 [TBL] [Abstract][Full Text] [Related]
8. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628 [TBL] [Abstract][Full Text] [Related]
9. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. Trojaniello C; Festino L; Vanella V; Ascierto PA Expert Rev Clin Pharmacol; 2019 Mar; 12(3):259-266. PubMed ID: 30652516 [TBL] [Abstract][Full Text] [Related]
10. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With Dummer R; Flaherty KT; Robert C; Arance A; de Groot JWB; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Schadendorf D; Yamazaki N; di Pietro A; Cantey-Kiser J; Edwards M; Ascierto PA J Clin Oncol; 2022 Dec; 40(36):4178-4188. PubMed ID: 35862871 [TBL] [Abstract][Full Text] [Related]
12. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819 [TBL] [Abstract][Full Text] [Related]
13. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. Gogas HJ; Flaherty KT; Dummer R; Ascierto PA; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Sileni VC; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Gollerkeri A; Pickard MD; Robert C Eur J Cancer; 2019 Sep; 119():97-106. PubMed ID: 31437754 [TBL] [Abstract][Full Text] [Related]
14. Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for Hamid O; Cowey CL; Offner M; Faries M; Carvajal RD Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31653096 [TBL] [Abstract][Full Text] [Related]
15. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials. Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321 [TBL] [Abstract][Full Text] [Related]
16. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. Johnson DB; Flaherty KT; Weber JS; Infante JR; Kim KB; Kefford RF; Hamid O; Schuchter L; Cebon J; Sharfman WH; McWilliams RR; Sznol M; Lawrence DP; Gibney GT; Burris HA; Falchook GS; Algazi A; Lewis K; Long GV; Patel K; Ibrahim N; Sun P; Little S; Cunningham E; Sosman JA; Daud A; Gonzalez R J Clin Oncol; 2014 Nov; 32(33):3697-704. PubMed ID: 25287827 [TBL] [Abstract][Full Text] [Related]
17. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077 [TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison. Atkins MB; Tarhini A; Rael M; Gupte-Singh K; O'Brien E; Ritchings C; Rao S; McDermott DF Immunotherapy; 2019 May; 11(7):617-629. PubMed ID: 30852924 [TBL] [Abstract][Full Text] [Related]
19. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. Richman J; Martin-Liberal J; Diem S; Larkin J Expert Opin Pharmacother; 2015 Jun; 16(9):1285-97. PubMed ID: 26001180 [TBL] [Abstract][Full Text] [Related]
20. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. Broman KK; Dossett LA; Sun J; Eroglu Z; Zager JS Expert Opin Drug Saf; 2019 May; 18(5):381-392. PubMed ID: 30977681 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]